Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor (Q38515085)

3 September 2017

1 reference

title

Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor (English)

1 reference

3 September 2017

0 references

1 reference

1 reference

Damayanthi Devineni

1

1 reference

PubMed ID

26041408

3 September 2017

David Polidori

series ordinal

2

1 reference

3 September 2017

4 June 2015

1 reference

Clinical Pharmacokinetics

3 September 2017

1 reference

3 September 2017

54

1 reference

3 September 2017

1027-1041

1 reference

3 September 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1007/s40262-015-0285-z

3 September 2017

0 references

cites work

Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Global cardiovascular disease risk assessment in United States adults with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Biology of human sodium glucose transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Canagliflozin: a review of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0285-Z

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

21 January 2018

1 reference

12 December 2020

Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.

1 reference

12 December 2020

Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers

1 reference

12 December 2020

Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results

1 reference

12 December 2020

Physiological parameters in laboratory animals and humans

1 reference

12 December 2020

Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants

1 reference

12 December 2020

Preclinical pharmacokinetics of statins.

1 reference

12 December 2020

Glyburide protein binding and the effect of albumin glycation in children, young adults, and older adults with diabetes

1 reference

12 December 2020

Plasma protein binding of warfarin: methodological considerations

1 reference

12 December 2020

Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects

1 reference

12 December 2020

Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants.

1 reference

12 December 2020

Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants

1 reference

12 December 2020

10.1007/S40262-015-0285-Z

Identifiers

DOI

1 reference

PubMed ID

26041408

Dimensions Publication ID

3 September 2017

0 references

1 reference

PubMed ID

26041408